Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms INPULSIS; INPULSIS-2
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 06 Aug 2019 Results from the INPULSIS and INPULSIS-ON trials assessing outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis published in the Respiratory Medicine
    • 15 Jun 2019 Results evaluating the safety and tolerability of Nintedanib at 52 weeks from SENSCI, INPULSIS-1 and INPULSIS-2 studies are presented at the 20th Annual Congress of the European League Against Rheumatism
    • 07 Feb 2019 Pooled results from NCT01335464 and NCT01335477 studies were published in the Advances in Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top